Published in Oncogene on October 01, 2007
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4. Oncogene (2012) 0.94
Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey. Cancer Microenviron (2014) 0.92
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res (2014) 0.92
Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Res (2014) 0.90
A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene (2010) 0.90
Influence of Hoxa5 on p53 tumorigenic outcome in mice. Am J Pathol (2009) 0.89
MTBP plays a crucial role in mitotic progression and chromosome segregation. Cell Death Differ (2011) 0.89
Haploinsufficiency of Tumor Suppressor Genes is Driven by the Cumulative Effect of microRNAs, microRNA Binding Site Polymorphisms and microRNA Polymorphisms: An In silico Approach. Cancer Inform (2012) 0.82
MTBP inhibits migration and metastasis of hepatocellular carcinoma. Clin Exp Metastasis (2015) 0.77
MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin. Dig Dis Sci (2015) 0.76
Haploinsufficiency of the Myc regulator Mtbp extends survival and delays tumor development in aging mice. Aging (Albany NY) (2016) 0.75
Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis. Hepatoma Res (2016) 0.75
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet (2001) 4.23
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ (2006) 2.95
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol (1994) 2.68
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J (1999) 2.64
Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ (2010) 2.43
Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci U S A (1998) 2.11
p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun (2005) 2.03
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell (2001) 1.88
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev (1997) 1.88
The p53-Mdm2 network in progenitor cell expansion during mouse postnatal development. J Pathol (2007) 1.83
NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J Biol Chem (1994) 1.73
High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A (2000) 1.73
Analysis of p53 mutants for transcriptional activity. Mol Cell Biol (1991) 1.73
Tissue-specific expression of the mouse alpha 2(I) collagen promoter. Studies in transgenic mice and in tissue culture cells. J Biol Chem (1992) 1.69
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene (2001) 1.66
A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene (2007) 1.55
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst (1998) 1.46
Isolation and characterization of genomic DNA coding for alpha 2 type I collagen. Nucleic Acids Res (1980) 1.43
mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene (1996) 1.40
Reduced amounts of cartilage collagen fibrils and growth plate anomalies in transgenic mice harboring a glycine-to-cysteine mutation in the mouse type II procollagen alpha 1-chain gene. Proc Natl Acad Sci U S A (1991) 1.37
Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells. Oncogene (2007) 1.35
Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. J Pathol (1999) 1.32
The loss of mdm2 induces p53-mediated apoptosis. Oncogene (2000) 1.31
Mutation of phosphoserine 389 affects p53 function in vivo. J Biol Chem (1996) 1.31
SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene (1993) 1.31
Apoptosis-inducing factor mediates microglial and neuronal apoptosis caused by pneumococcus. J Infect Dis (2001) 1.30
p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene (2009) 1.29
Selective regulation of Bcl-XL by a Jak kinase-dependent pathway is bypassed in murine hematopoietic malignancies. Genes Dev (1998) 1.24
Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice. J Virol (1987) 1.24
Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality. Oncogene (2008) 1.21
Crippling p53 activities via knock-in mutations in mouse models. Oncogene (2007) 1.19
The cenpB gene is not essential in mice. Chromosoma (1998) 1.17
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ (2008) 1.17
p53 sends nucleotides to repair DNA. Nature (2000) 1.16
A distinct class of vertebrate collagen genes encodes chicken type IX collagen polypeptides. Proc Natl Acad Sci U S A (1985) 1.15
Structure of the glycosaminoglycan domain in the type IX collagen-proteoglycan. Proc Natl Acad Sci U S A (1987) 1.11
The effect of agility ankle prosthesis misalignment on the peri-ankle ligaments. Clin Orthop Relat Res (2004) 1.08
The tumor suppressor p53 regulates its own transcription. Mol Cell Biol (1993) 1.08
Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene (2000) 1.07
Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res (1998) 1.05
Construction and characterization of cDNA encoding the alpha 2 chain of chicken type IX collagen. Biochemistry (1985) 1.03
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene (2010) 0.99
The effect of incongruity and instability on contact stress directional gradients in human cadaveric ankles. Osteoarthritis Cartilage (2008) 0.97
Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene (1997) 0.97
The mutant p53 mouse as a pre-clinical model. Oncogene (2013) 0.97
Renal hydatid cysts: communicating with collecting system. AJR Am J Roentgenol (1980) 0.96
The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. Biochem Biophys Res Commun (1999) 0.96
Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene (2006) 0.93
Isolation of the Aspergillus nidulans sudD gene and its human homologue. Gene (1998) 0.92
E2F-1 induces the stabilization of p53 but blocks p53-mediated transactivation. Oncogene (2001) 0.92
Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. Radiat Res (1997) 0.91
Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet (1998) 0.91
The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today (1997) 0.90
The organization and expression of the mdm2 gene. Genomics (1996) 0.90
A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis. Oncogene (2010) 0.90
MTBP plays a crucial role in mitotic progression and chromosome segregation. Cell Death Differ (2011) 0.89
Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest (1995) 0.89
Aging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression. Oncogene (2011) 0.89
Nonsuppressible insulin-like activity (NSILA). II. Regulation of serum concentrations by growth hormone and insulin. J Clin Endocrinol Metab (1978) 0.89
An in vivo battery for identifying endocrine modulators that are estrogenic or dopamine regulators. Fundam Appl Toxicol (1996) 0.89
Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma. Oncogene (2011) 0.88
An intron binding protein is required for transformation ability of p53. Nucleic Acids Res (1991) 0.88
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ (2012) 0.88
p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells. Cell Death Differ (2002) 0.87
Transcriptional mechanisms controlling types I and III collagen genes. Ann N Y Acad Sci (1990) 0.87
Mutant p53 protein, master regulator of human malignancies: a report on the Fifth Mutant p53 Workshop. Cell Death Differ (2011) 0.87
Short-chain collagen genes and their expression in cartilage. Ann N Y Acad Sci (1985) 0.87
Suppression of Ras/Mapk pathway signaling inhibits Myc-induced lymphomagenesis. Cell Death Differ (2012) 0.87
The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene (1997) 0.86
Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg (2001) 0.86
Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol (2001) 0.85
Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice. Brain Res (1986) 0.84
90-day feeding and one-generation reproduction study in Crl:CD BR rats with 17 beta-estradiol. Toxicol Sci (1998) 0.84
cDNA library screening using the SOS recruitment system. Biotechniques (2001) 0.83
Cyclin E restores p53 activity in contact-inhibited cells. Mol Cell Biol (1995) 0.83
Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. Cell Growth Differ (1999) 0.83
An immunocytochemical study of pituitary adenomas and focal hyperplasia in old Sprague-Dawley and Fischer 344 rats. Toxicol Pathol (1988) 0.83
Structural and functional analysis of p53: the acidic activation domain has transforming capability. Cell Growth Differ (1994) 0.83
[Popular notions regarding "dengue" and "rompehuesos", 2 models of the disease in Colombia]. Rev Panam Salud Publica (2001) 0.83
Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis. Cell Death Differ (2013) 0.83
Stance-phase aggregate contact stress and contact stress gradient changes resulting from articular surface stepoffs in human cadaveric ankles. Osteoarthritis Cartilage (2005) 0.83
Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature (2015) 0.81
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. Nat Genet (1997) 0.81
Role of prolactin in chloro-S-triazine rat mammary tumorigenesis. Drug Chem Toxicol (2000) 0.81
Organization, expression, and localization of the murine mdmx gene and pseudogene. Gene (2001) 0.80
Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. Oncogene (1996) 0.80
Genetic markers associated with progression in early mycosis fungoides. J Eur Acad Dermatol Venereol (2013) 0.80
Differential expression of a Mr approximately 90,000 cell surface transferrin receptor-related glycoprotein on murine B16 metastatic melanoma sublines selected for enhanced brain or ovary colonization. Cancer Res (1990) 0.79